Rituximab is a monoclonal antibody that selectively targets CD20-expressing B cells, offering a substantial benefit in both autoimmune diseases and B-cell malignancies, especially in patients who have not responded to TNF inhibitors. The gene discussed is TNF; the disease is autoimmune disease.